Cargando…

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection

SIMPLE SUMMARY: Prostate cancer remains one of the leading causes of death in men in the United States. The commonly utilized method of diagnosing prostate cancer is via the digital rectal examination and serum PSA assay, which is usually followed by biopsy of the prostate gland to evaluate the exte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Höti, Naseruddin, Lih, Tung-Shing, Dong, Mingming, Zhang, Zhen, Mangold, Leslie, Partin, Alan W., Sokoll, Lori J., Kay Li, Qing, Zhang, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913326/ https://www.ncbi.nlm.nih.gov/pubmed/36765916 http://dx.doi.org/10.3390/cancers15030960

Ejemplares similares

Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA
por: Wang, Ce, et al.
Publicado: (2019)

Urinary glycoproteins associated with aggressive prostate cancer
por: Dong, Mingming, et al.
Publicado: (2020)

Urinary marker panels for aggressive prostate cancer detection
por: Lih, Tung-Shing Mamie, et al.
Publicado: (2022)

Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers
por: Li, Qing Kay, et al.
Publicado: (2015)

Characterisation of the main PSA glycoforms in aggressive prostate cancer
por: Gratacós-Mulleras, Anna, et al.
Publicado: (2020)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer
por: Song, Jin, et al.
Publicado: (2021)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Temperature Control of psaA Expression by PsaE and PsaF in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2019)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

HSP27/Menin Expression as New Prognostic Serum Biomarkers of Prostate Cancer Aggressiveness Independent of PSA
por: Bourefis, Asma, et al.
Publicado: (2022)

Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors
por: Li, Qing Kay, et al.
Publicado: (2021)

Low Levels of Urinary PSA Better Identify Prostate Cancer Patients
por: Occhipinti, Sergio, et al.
Publicado: (2021)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Fasting times in serum PSA assay
por: Xu, Xiang, et al.
Publicado: (2014)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer
por: Tang, Qionghua, et al.
Publicado: (2022)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity
por: Mattsson, Johanna M., et al.
Publicado: (2014)

Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
por: Lee, Jaegeun, et al.
Publicado: (2021)

Re: Fasting times in serum PSA assay
por: Lau, Cheryl K, et al.
Publicado: (2014)

Is serum PSA a predictor of male hypogonadism?
Publicado: (2021)

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

Lower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise?
por: Just, Jasmine, et al.
Publicado: (2018)

Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer
por: Fujita, Kazutoshi, et al.
Publicado: (2016)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions
por: Flores-Fraile, María-Carmen, et al.
Publicado: (2020)

Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis
por: Wang, Wenying, et al.
Publicado: (2014)

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
por: Kotb, A F, et al.
Publicado: (2011)

Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements
por: McJimpsey, Erica L.
Publicado: (2016)

Incidence of Histological Prostatitis and Its Correlation with PSA Density
por: Piovesan, Affonso Celso, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_6jgp2q5qbolin9qju6jred4nt9